Kura Oncology Inc Stock Price, News & Analysis

Kura Oncology (NASDAQ:KURA), a clinical-stage biopharmaceutical company focused on precision medicines for cancer treatment, has announced its participation in three major investor conferences in September 2025.

The company will present at the Cantor Global Health Conference on September 4 at 8:35 a.m. ET, the H.C. Wainwright Global Investment Conference on September 8 at 1:00 p.m. ET, and the Morgan Stanley Global Healthcare Conference on September 10 at 1:50 p.m. ET. Live webcasts will be available on Kura's website with archived replays accessible after the events.

Kura Oncology (NASDAQ: KURA) reported Q2 2025 financial results and significant progress in its oncology pipeline. The FDA granted Priority Review for ziftomenib in relapsed/refractory NPM1-mutant AML with a PDUFA date of November 30, 2025. The company reported $15.3 million in collaboration revenue and ended Q2 with $630.7 million in cash.

Key clinical achievements include positive results from the KOMET-001 pivotal trial showing a 23% complete remission rate and promising data from KOMET-007 Phase 1b expansion cohort. The company plans to initiate two Phase 3 trials in frontline AML settings in 2H 2025 and will present three clinical abstracts from its FTI program at the 2025 ESMO Congress.

Q2 2025 resulted in a net loss of $66.1 million, with R&D expenses of $62.8 million and G&A expenses of $25.2 million. Current cash runway extends into 2027.

Kura Oncology (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on precision medicines for cancer treatment, has announced inducement grants to 35 new employees. The Compensation Committee approved nonstatutory stock options to purchase 646,700 shares of common stock under the company's 2023 Inducement Option Plan.

The stock options have an exercise price of $6.02 per share, matching the closing price on August 1, 2025. These options will vest over four years, with 25% vesting after one year and the remaining balance vesting monthly over 36 months, contingent on continued employment.

Kura Oncology (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on precision medicines for cancer treatment, has scheduled its second quarter 2025 financial results announcement for Thursday, August 7, 2025, after U.S. market close.

The company will host a conference call and webcast at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results and provide a corporate update. Investors can access the call via phone or webcast through the company's investor relations website.

Kura Oncology (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on precision cancer medicines, has announced inducement grants to eight new employees. The Compensation Committee approved nonstatutory stock options to purchase 141,750 shares of common stock under the company's 2023 Inducement Option Plan.

The stock options have an exercise price of $5.60 per share, based on the closing price on July 1, 2025. The options will vest over four years, with 25% vesting after one year and the remainder vesting monthly over 36 months, contingent on continued employment.

Kura Oncology and Kyowa Kirin reported positive Phase 1a/1b trial results for ziftomenib combined with 7+3 chemotherapy in newly diagnosed AML patients. The KOMET-007 trial showed impressive complete remission rates of 93% in NPM1-mutant and 89% in KMT2A-rearranged AML patients. Notable MRD-negativity rates were achieved: 71% in NPM1-m and 88% in KMT2A-r patients. The treatment demonstrated favorable safety with no additive myelosuppression. High survival rates were observed with 96% of NPM1-m and 88% of KMT2A-r patients remaining alive and on study. Phase 3 studies (KOMET-017-IC and NIC) are planned to start in second half of 2025. The data suggests ziftomenib's potential as a frontline treatment option for AML patients.

Kura Oncology (NASDAQ: KURA) announced the granting of inducement awards to five new employees on June 2, 2025. The awards consist of nonstatutory stock options to purchase 79,200 shares of common stock under the Company's 2023 Inducement Option Plan. The stock options have an exercise price of $6.30 per share, matching the company's closing price on the grant date. The options will vest over four years, with 25% vesting after one year and the remaining balance vesting monthly over the following 36 months, contingent on continued employment. These grants were approved by the Compensation Committee as inducement material for employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Kura Oncology and Kyowa Kirin presented positive pivotal Phase 2 trial results for ziftomenib, their oral menin inhibitor, in treating relapsed/refractory NPM1-mutated AML patients. The drug achieved a 23% CR/CRh rate (21/92 patients) with 63% of evaluable responders achieving MRD-negative status. The treatment showed consistent efficacy across subgroups and demonstrated a favorable safety profile with only 3% discontinuation rate due to treatment-related adverse events. Notably, responders showed a median overall survival of 16.4 months compared to 3.5 months for non-responders. With a PDUFA date of November 30, 2025, ziftomenib could become the first FDA-approved therapy specifically for NPM1-mutated AML, which represents approximately 30% of AML cases.

The FDA has accepted Kura Oncology and Kyowa Kirin's New Drug Application (NDA) for ziftomenib, granting Priority Review for treating adult patients with relapsed or refractory NPM1-mutant acute myeloid leukemia (AML). The PDUFA target action date is set for November 30, 2025. The NDA is supported by positive results from the Phase 2 KOMET-001 trial, which met its primary endpoint of complete remission plus CR with partial hematological recovery. Ziftomenib demonstrated a favorable safety profile with limited myelosuppression and only 3% treatment-related discontinuations. The drug has received multiple FDA designations including Breakthrough Therapy, Fast Track, and Orphan Drug. If approved, ziftomenib would be the first menin inhibitor for treating this aggressive form of AML.